Altered molecular weight forms of adiponectin in hypertension

Journal of Clinical Hypertension

Volumn 11, Issue 1, 2009, Pages 11-16

  Baumann, Marcus ^a   Von Eynatten, Maximilian ^a   Dan, Liu ^a   Richart, Tom ^b,c   Kouznetsova, Tatiana ^c   Heemann, Uwe ^a   Staessen, Jan A ^b,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; MALE; MOLECULAR WEIGHT; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; WESTERN BLOTTING;

ADIPONECTIN; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; STATISTICS, NONPARAMETRIC;

EID: 58149456656     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.00057.x     Document Type: Article

References (22)

1. Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 2005;293(15):1868-1874.
2. Von Eynatten M, Liu D, Bluemm A, et al. Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes. Clin Endocrinol. 2008. Epub ahead of print.
3. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439-451.
4. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: An adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002;13:84-89.
5. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595-1599.
6. Koenig W, Khuseyinova N, Baumert J, et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: Results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006;48:1369-1377.
7. Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;43:1318-1323.
8. Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension. 2007;51:8-14.
9. Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem. 2003;278:9073-9085.
10. Basu R, Pajvani UB, Rizza RA, et al. Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: Differential regulation from nondiabetic subjects. Diabetes. 2007;56(8):2174-2177.
11. Aso Y, Yamamoto R, Wakabayashi S, et al. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes. 2006;55:1954-1960.
12. Zhang H, Thijs L, Kuznetsova T, et al. Progression to hypertension in the non-hypertensive participants in the Flemish Study on Environment, Genes and Health Outcomes. J Hypertens. 2006;24:(9):1719-1727.
13. Malik RA, Schofield IJ, Izzard A, et al. Effects of angiotensin type-1 receptor antagonism on small artery function in patients with type 2 diabetes mellitus. Hypertension. 2005;45:(2):264-269.
14. Bobbert T, Rochlitz H, Wegewitz U, et al. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes. 2005;54:2712-2719.
15. Chow WS, Cheung BM, Tso AW, et al. Hypoadiponectinemia as a predictor for the development of hypertension: A 5-year prospective study. Hypertension. 2007;49:1455-1461.
16. Della MeaP, Lupia M, Bandolin V, et al. Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. Am J Hypertens. 2005;18:30-35.
17. Lara-Castro C, Luo N, Wallace P, et al. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes. 2006;55:249-259.
18. Von Eynatten M, Humpert PM, Bluemm A, et al. High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis 2008;199(1):123-128.
19. Okamoto Y, Arita Y, Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res. 2000;32:47-50.
20. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103:1057-1063.
21. Kobayashi H, Ouchi N, Kihara S, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res. 2004;94:e27-e31.
22. Schmieder RE, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007;30:(6)1351-1356.